Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 6/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL586871 | 0.92 | EPHX2 (0.39) | NOTUMKDM1AEPHX2TRPM8 | |
| SCHEMBL581075 | 0.89 | NOTUM (0.39) | NOTUMEPHX2 | |
| SCHEMBL582069 | 0.89 | EPHX2 (0.42) | NOTUMKDM1AEPHX2TRPM8 | |
| SCHEMBL580676 | 0.88 | FFAR2 (0.41) | KDM1A | |
| SCHEMBL581460 | 0.88 | KDM1A (0.46) | NOTUMKDM1AEPHX2TRPM8CHRM2 | |
| SCHEMBL581653 | 0.86 | NOTUM (0.37) | NOTUM | |
| SCHEMBL580878 | 0.85 | OPRK1 (0.40) | NOTUMDRD4CHRNA3DRD3 | |
| SCHEMBL581628 | 0.85 | EPHX2 (0.44) | KDM1AEPHX2TRPM8 | |
| SCHEMBL587515 | 0.84 | FFAR2 (0.39) | — | |
| SCHEMBL582132 | 0.83 | NOTUM (0.47) | NOTUMEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| CN-102459246-A | Isoxazol-3 (2H) -one analogs as therapeutic agents | ASTRAZENECA AB | 2012-05-16 | — | — | CN | disclosed |
| EP-2417131-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117323-A1 | METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | WO | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | NOTUM 2559/4885KDM1A 4032/4885EPHX2 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.